Quick Answer
Compass Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $30.64 million for the year ending 2025.
- Compass Therapeutics, Inc. showed a decrease of -29.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $7.2 thousand | Q3 2018: $2.4 thousand | Q4 2018: $4.7 thousand | Q2 2019: $4.9 thousand | Q3 2019: $882.00 | Q2 2020: $65.37 million | Q3 2020: $55.52 million | Q1 2021: $39.70 million | Q2 2021: $31.21 million | Q3 2021: $25.51 million | Q1 2022: $136.38 million | Q2 2022: $26.24 million | Q3 2022: $16.48 million | Q1 2023: $27.03 million | Q2 2023: $19.28 million | Q3 2023: $30.43 million | Q1 2024: $43.48 million | Q2 2024: $19.40 million | Q3 2024: $19.40 million | Q1 2025: $41.05 million | Q2 2025: $22.86 million | Q3 2025: $46.21 million.
- Over the full 9 years of available data (2019 to 2025), Compass Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 629,637.0%.
- Historical annual values: Fiscal year 2025: $30.64 million | Fiscal year 2024: $43.48 million | Fiscal year 2023: $24.23 million | Fiscal year 2022: $34.95 million | Fiscal year 2021: $144.51 million | Fiscal year 2020: $47.08 million | Fiscal year 2020: $3.7 thousand | Fiscal year 2019: $25.30 million | Fiscal year 2019: $4.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: